November/December 2014, Issue 2

November/December 2014

Issue 2

This issue features an update from the ASH Choosing Wisely Task Force, a look at the first wave of Sunshine Act data, a debate over radiation therapy in Hodgkin lymphoma, and more.

Table of Contents

November/December 2014

Belonging to a Club That Would Have Me as a Member

Saturday, November 1st, 2014
Even though I had practiced my oral presentation a bunch of times, I still cringed when the session moderator announced the abstract number, title,...

Managing Atrial Fibrillation: The Cardiologist’s Perspective

Saturday, November 1st, 2014
Dr. Flaker is also a member of the American College of Cardiology’s (ACC’s) Anticoagulation Initiative Work Group – a multidisciplinary quality effort to address...

What Should You Call Us?

Saturday, November 1st, 2014
Nurse practitioners, clinical nurse specialists, nurse anesthetists, nurse midwives, and physician’s assistants (PAs) are like most hematologic cancers and blood disorders: heterogeneous in presentation....

November/December 2014

The Votes Are In…ASH Announces Executive Committee Election Results

Saturday, November 1st, 2014
The Votes Are In...ASH Announces Executive Committee Election Results On October 14, the American Society of Hematology announced the election of four new members...

High-Cost and High-Demand: New ASH Drug Access Web Page Provides Resources for Clinicians and...

Saturday, November 1st, 2014
Hematologic drugs are expensive and often available only in specialty tiers of prescription drug plans – presenting several barriers to access. To help ensure...

November-December 2014

“Still” Photography (Part 2 of 2) by Jason Gotlib, MD, MS

Saturday, November 1st, 2014
Part 2 of his essay and additional photographs appear here. Dr. Gotlib is the editor-in-chief designee for The Hematologist; his term will begin in...

Is There Still a Need for Radiation Therapy in Hodgkin Lymphoma?

Saturday, November 1st, 2014
The standard treatment for certain types of Hodgkin lymphoma is combined modality therapy – consisting of chemotherapy followed by radiation therapy. Recently, there has...

Pulling Back the Curtain: Joseph R. Mikhael, MD, MEd 

Saturday, November 1st, 2014
What was your first job? My first job was as a camp counselor, and this actually turned out to be a great job because it...

Physicians Still Foggy on Accuracy of Sunshine Act Data

Saturday, November 1st, 2014
On September 30, the Centers for Medicare & Medicaid Services (CMS) released the first round of Open Payments data. More than 4 million payments...

New IMWG Diagnostic Criteria Allows Earlier Diagnosis

Saturday, November 1st, 2014
Updates Represent a “Paradigm Shift” for Multiple Myeloma Treatment Unlike other malignancies, the disease definition of multiple myeloma is clinicopathological: not only must myeloma be...

Improving Care Through Technology, Policy, and Philanthropy

Saturday, November 1st, 2014
David Blumenthal, MD, heard the call to public service at an early age. His professional career has ranged from primary-care clinical practice to government service...

November/December 2014

Understanding MDS

Saturday, November 1st, 2014
Myelodysplastic syndromes (MDS) are a group of diseases of the bone marrow and blood that affect approximately 19,000 people in the United States. For...

From the Hudson River to the Hematology Wards: Why Simulation of Intrathecal Chemotherapy Can...

Saturday, November 1st, 2014
Let’s start with two case examples: “Mr. M” is a 36-year-old male with newly diagnosed B-cell acute lymphocytic leukemia (ALL) who presents with diplopia,...

Ten Things Doctors and Patients Should Question: An Update from the Choosing Wisely Task...

Saturday, November 1st, 2014
Choosing Wisely®, an initiative of the American Board of Internal Medicine (ABIM) Foundation, is a campaign that encourages clinicians and patients to engage in...

Is pegfilgrastim with ABVD in Hodgkin lymphoma necessary?

Saturday, November 1st, 2014
This month, Sonali M. Smith, MD, advises on the use of pegfilgrastim with ABVD for treating Hodgkin lymphoma. What is your opinion on the use...

November/December 2014

WIB_icon

Biologics Before Chemotherapy: Treatment Updates for Mycosis Fungoides, Sézary Syndrome

Saturday, November 1st, 2014
The use of chemotherapy to treat mycosis fungoides and Sézary syndrome, the most common forms of cutaneous T-cell lymphomas, led to a shorter time...

Panobinostat Improves Survival in Multiple Myeloma: Results from PANORAMA1

Saturday, November 1st, 2014
A three-drug combination with panobinostat significantly increased median progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma. Adding panobinostat to the multiple myeloma treatment...
WIB_icon

Off-Label Rituximab Proves Its Mettle in Adult ITP

Saturday, November 1st, 2014
For adult patients with persistent or chronic immune thrombocytopenia (ITP), off-label treatment with rituximab proved a safe and effective management option, according to results...

Barcoding Stem Cells Add to Understanding of Hematopoietic Disease

Saturday, November 1st, 2014
A barcoding and tracking system for tissue stem cells has revealed previously unrecognized features of normal blood production: Surprisingly, the billions of blood cells...
WIB_icon

Pre-Procedure Anticoagulation Interruption May Not Be Necessary

Saturday, November 1st, 2014
Patients with atrial fibrillation (AF) on anticoagulation therapies who require a surgical procedure may require an interruption in the therapy – depending on their...

The AG-221 Study, ASPIRE, and More

Saturday, November 1st, 2014
LEUKEMIA TRIALS Phase I Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation (NCT01915498)  Study design: Open-label, single-group assignment safety study ...

Updates on Idelalisib, A New Treatment for Acquired Hemophilia A, and More

Saturday, November 1st, 2014
DEA Places New Restrictions on Vicodin and other Pain Medicines Effective October 6, 2014, the US Food and Drug Administration rescheduled hydrocodone combination products (HCPs)...
WIB_icon

Obesity Has Early and Lasting Effects on Children with ALL

Saturday, November 1st, 2014
For children with B-precursor acute lymphocytic leukemia (BP-ALL), having a BMI ≥30 kg/m2 at the time of treatment initiation more than doubled the likelihood...

New Hope in High-Risk Leukemia Subtype

Saturday, November 1st, 2014
Philadelphia chromosome-like acute lymphocytic leukemia (Ph-like ALL) is a precursor of B-cell ALL. Unfortunately, pediatric patients with Ph-like ALL face worse outcomes. Adding tyrosine...
WIB_icon

MPL Expression Necessary for Development of Jak2V617F-Induced MPN

Saturday, November 1st, 2014
Results of a preclinical study showed that ablating the thrombopoietin (TPO) receptor (MPL) in Jak2V617F-positive mice prevented the development of myeloproliferative neoplasms (MPNs). The...
WIB_icon

Remission Duration Key to Survival in CLL After FCR

Saturday, November 1st, 2014
In spite of the efficacy of the treatment regimen of fludarabine, cyclophosphamide, and rituximab (FCR) in chronic lymphocytic leukemia (CLL), most CLL patients are...

The New Normal: Lower Transfusion Thresholds for Septic Shock Patients

Saturday, November 1st, 2014
A restrictive approach to blood transfusion reduced blood use by half but, more importantly, caused no harm to 998 critically ill patients with septic...

November/December 2014

ASH 2014 Annual Meeting Preview: The Rising Cost of Medical Care

Saturday, November 1st, 2014
Understanding the Problems and Exploring Solutions Health-care spending in the United States is a growing problem: in 2011, health-care spending was estimated at $2.7 trillion,...

SHARE